Access and support

Supporting your patients as they take their next step with extended adjuvant therapy

Enrollment form

Access and reimbursement support for NERLYNX

For patients prescribed with NERLYNX tablets, Puma Patient Lynx provides the following support services:

  • 3-Month Supply of Anti-diarrheals Voucher program for a free 3-month supply of anti-diarrheals is available to eligible patients.*
  • Benefits Verification and Prior Authorization Assistance Our reimbursement counselors will conduct a benefits investigation, verify insurance approval or coverage, and obtain and submit necessary documentation for patients requiring prior authorization.
  • NERLYNX Quick Start Provides a free 3-week supply of NERLYNX to eligible patients experiencing delays in gaining access to therapy.
  • Co-Pay Assistance Puma Biotechnology offers co-pay assistance to help qualified insured patients with the out-of-pocket costs associated with their NERLYNX prescription.
  • Financial Support For patients with financial needs, we will work to find appropriate sources for support.

Ongoing treatment support

For patients currently taking NERLYNX, Puma Patient Lynx provides the following services:

  • NERLYNX Mentor Program Available to all women with early-stage HER2+ breast cancer who are considering NERLYNX but have not started treatment.
  • Product Support Our specialty pharmacy network will provide patients with product education and side-effect counseling to help them better understand and manage their NERLYNX therapy.
  • Nurse Call Center Our nurses are available to speak to patients and healthcare providers to answer questions about NERLYNX. The call center is open 24 hours a day, 7 days a week for your convenience.
  • Text Message Support Program Patients can sign up to receive medication reminders and motivational messages to support treatment adherence.

*Not valid for prescriptions purchased under Medicaid, Medicare, TRICARE, or similar federal or state programs or for patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.

For more information on the Puma Patient LynxSupport Program: 1-855-816-5421, Monday–Friday, 9 AM–8 PM ET


NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.



ADVERSE REACTIONS: The most common adverse reactions (>5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and or FDA at 1-800-FDA-1088 or



For Full Prescribing Information, please click here.